Physician profile
David J Bateman
NPI 1871852301
$541.00
in general payments reported to CMS, 2019-2025
13 companies · $14.62 in 2025
The $14.62 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.71 · 2021: $37.66 · 2022: $167 · 2023: $105 · 2024: $139 · 2025: $14.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186.90 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $69.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $67.20 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.85 | 2024 | Lifevest |
| Vifor Pharma, INC. | $31.77 | 2019-2021 | |
| Breas Medical, INC. | $26.96 | 2024 | Vivo 45 Ls |
| Alexion Pharmaceuticals, INC. | $23.75 | 2022 | |
| Gilead Sciences, INC. | $21.72 | 2023 | |
| Philips North America LLC | $20.07 | 2023 | |
| Melinta Therapeutics, LLC | $14.96 | 2019 | |
| Lilly USA, LLC | $14.62 | 2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $14.31 | 2022 | |
| Merck Sharp & Dohme LLC | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bateman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.